These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 30830269)

  • 1. Absolute numbers of regulatory T cells and neutrophils in corticosteroid-free patients are predictive for response to bevacizumab in recurrent glioblastoma patients.
    Quillien V; Carpentier AF; Gey A; Avril T; Tartour E; Sejalon F; Campillo-Gimenez B; Vauleon E
    Cancer Immunol Immunother; 2019 Jun; 68(6):871-882. PubMed ID: 30830269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study.
    Morisse MC; Etienne-Selloum N; Bello-Roufai D; Blonski M; Taillandier L; Lorgis V; Noël G; Ahle G; Durán-Peña A; Boone M; Chauffert B
    J Neurooncol; 2019 Sep; 144(2):419-426. PubMed ID: 31325146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4
    Bota DA; Chung J; Dandekar M; Carrillo JA; Kong XT; Fu BD; Hsu FP; Schönthal AH; Hofman FM; Chen TC; Zidovetzki R; Pretto C; Strik A; Schijns VE; Stathopoulos A
    CNS Oncol; 2018 Jul; 7(3):CNS22. PubMed ID: 30157683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.
    Petrova L; Korfiatis P; Petr O; LaChance DH; Parney I; Buckner JC; Erickson BJ
    J Neurol Sci; 2019 Oct; 405():116433. PubMed ID: 31476621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
    Pasqualetti F; Pace A; Gonnelli A; Villani V; Cantarella M; Delishaj D; Vivaldi C; Molinari A; Montrone S; Pellerino A; Franchino F; Baldaccini D; Lombardi G; Lolli I; Catania F; Bazzoli E; Morganti R; Fabi A; Zagonel V; Bocci G; Fabrini MG; Rudà R; Soffietti R; Paiar F
    Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased infiltration of CD8 T cells in recurrent glioblastoma patients is a useful biomarker for assessing the response to combined bevacizumab and lomustine therapy.
    Lin P; Jiang H; Zhao YJ; Pang JS; Liao W; He Y; Lin ZY; Yang H
    Int Immunopharmacol; 2021 Aug; 97():107826. PubMed ID: 34091114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR amplification and classical subtype are associated with a poor response to bevacizumab in recurrent glioblastoma.
    Hovinga KE; McCrea HJ; Brennan C; Huse J; Zheng J; Esquenazi Y; Panageas KS; Tabar V
    J Neurooncol; 2019 Apr; 142(2):337-345. PubMed ID: 30680510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.
    Bertaut A; Truntzer C; Madkouri R; Kaderbhai CG; Derangère V; Vincent J; Chauffert B; Aubriot-Lorton MH; Farah W; Mourier KL; Boidot R; Ghiringhelli F
    Oncotarget; 2016 Oct; 7(43):70948-70958. PubMed ID: 27487142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
    Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
    J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
    Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
    Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma.
    Pace A; Mandoj C; Antenucci A; Villani V; Sperduti I; Casini B; Carosi M; Fabi A; Vidiri A; Koudriavtseva T; Conti L
    J Neurooncol; 2018 Jul; 138(3):527-535. PubMed ID: 29594657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasmatic MMP9 released from tumor-infiltrating neutrophils is predictive for bevacizumab efficacy in glioblastoma patients: an AVAglio ancillary study.
    Jiguet-Jiglaire C; Boissonneau S; Denicolai E; Hein V; Lasseur R; Garcia J; Romain S; Appay R; Graillon T; Mason W; Carpentier AF; Brandes AA; Ouafik L'; Wick W; Baaziz A; Gigan JP; Argüello RJ; Figarella-Branger D; Chinot O; Tabouret E
    Acta Neuropathol Commun; 2022 Jan; 10(1):1. PubMed ID: 34980260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
    Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
    J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the apparent diffusion coefficient in patients with recurrent glioblastoma under treatment with bevacizumab with radiographic pseudoresponse.
    Auer TA; Breit HC; Marini F; Renovanz M; Ringel F; Sommer CJ; Brockmann MA; Tanyildizi Y
    J Neuroradiol; 2019 Feb; 46(1):36-43. PubMed ID: 29733920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third-line therapy in recurrent glioblastoma: is it another chance for bevacizumab?
    Franceschi E; Lamberti G; Paccapelo A; Di Battista M; Genestreti G; Minichillo S; Mura A; Bartolini S; Agati R; Brandes AA
    J Neurooncol; 2018 Sep; 139(2):383-388. PubMed ID: 29671196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
    Schaub C; Tichy J; Schäfer N; Franz K; Mack F; Mittelbronn M; Kebir S; Thiepold AL; Waha A; Filmann N; Banat M; Fimmers R; Steinbach JP; Herrlinger U; Rieger J; Glas M; Bähr O
    J Neurooncol; 2016 Aug; 129(1):93-100. PubMed ID: 27193554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan.
    Urup T; Dahlrot RH; Grunnet K; Christensen IJ; Michaelsen SR; Toft A; Larsen VA; Broholm H; Kosteljanetz M; Hansen S; Poulsen HS; Lassen U
    Acta Oncol; 2016; 55(4):418-22. PubMed ID: 26828563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leakage decrease detected by dynamic susceptibility-weighted contrast-enhanced perfusion MRI predicts survival in recurrent glioblastoma treated with bevacizumab.
    Hilario A; Sepulveda JM; Hernandez-Lain A; Salvador E; Koren L; Manneh R; Ruano Y; Perez-Nuñez A; Lagares A; Ramos A
    Clin Transl Oncol; 2017 Jan; 19(1):51-57. PubMed ID: 27026567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma.
    Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Ozcelik M; Esenkaya A; Saygi HM; Uzunoglu S; Cicin I
    Med Oncol; 2015 Feb; 32(2):460. PubMed ID: 25572814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of bevacizumab in the treatment of glioblastoma.
    Diaz RJ; Ali S; Qadir MG; De La Fuente MI; Ivan ME; Komotar RJ
    J Neurooncol; 2017 Jul; 133(3):455-467. PubMed ID: 28527008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.